Merck KGaA (MRK) Earnings Call Transcript & Summary
March 4, 2021
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and welcome to the Merck Investor and Analyst conference call covering the fourth quarter of 2020. <<operator_script>> At this point, I'd like to turn the call over to Constantin Fest, our Head of Investor Relations, who will guide you through today's conference. Please go ahead, sir.
Constantin Fest
executiveThanks a lot, Diana, and a really warm welcome to this Q4 and Full Year 2020 Earnings Call. I’m Constantin Fest, Head of Investor Relations at Merck. Just so you know, presenting today are Stefan Oschmann, our group CEO; Marcus Kuhnert, our Group CFO; and Kai Beckmann, CEO of our Electronics Business Sector, formerly PM. For a short introduction to the capital markets, Peter Guenter, our new CEO of our Healthcare business sector, is also on the call and will be available for the Q&A. Also, please note that Danny Bar-Zohar, our Healthcare Global Head of Development, is available for questions. Finally, I’m delighted to let you know that Belen Garijo, Vice Chair of the Executive Board and Deputy CEO of Merck, will join us for 1 or 2 minutes. After the presentation, for a brief message. With that, we’ll now guide you through the key slides of this presentation, and I will then be happy — all of us will then be happy to take all of your questions. Stefan?
Stefan Oschmann
executiveThanks. Thanks, Constantin, and a warm welcome from me as well. Welcome to our full year earnings call. I'm on Slide 4 of the presentation, beginning with the highlights. 2020 was an unprecedented year in many respects, and for Merck it was a successful year. That held true despite the challenges we faced amid the COVID-19 pandemic. Operational performance was strong, we continue to make excellent progress with our strategic agenda, and we delivered on our upgraded guidance. By sector, Healthcare had a solid year overall, with a broadly stable base business and significant growth of new products. At the same time, we advanced our pipeline further and rigorously managed our costs. Performance of Life Science was outstanding, with robust growth in the core business and significant contributions from COVID-19 related business. In addition, we further strengthened our leading market position through innovations and significantly invested in exciting areas for future growth. Performance Materials, which from now on will be called Electronics, saw a major boost due to consolidation benefits from Versum Materials and, most importantly, returned to sustainable organic growth in Q4. That said, we are looking ahead to 2021 with optimism. Our key growth engines, AKA, the big 3, are running full steam ahead.
Stefan Oschmann
executiveWe anticipate that profitable growth for the group will come from all 3 business sectors, with further details in our guidance to follow later. Slide 5 gives you a recap of the headline commitments we made last year. As you can see, every one of them was delivered. In fact, we even came in slightly ahead of our most recent organic growth projections, with group sales rising plus 6% and EBITDA pre increasing plus 8.4%. That figure leaves out currency and portfolio mix effects as well as the biogen provision release. Slide 6 shows the regional breakdown for the EUR 17.5 billion in sales we brought in last year. Importantly, positive organic growth was achieved in all major regions. Our footprint is also still balanced, with Asia Pacific at 36%, Europe at 28%; and North America at 27%. Turning to Slide 7 and the dividend. As this morning's release showed, we announced a dividend of EUR 1.4 per share for the AGM on April 23. That is an 8% increase over 2019 and a payout ratio of 23.1% of EPS pre, excluding the Biogen provision release. And it is fully consistent with our dividend policy, which targets continuous dividend growth in line with how our earnings develop.
Stefan Oschmann
executiveOur dedication to reducing debt on an ongoing basis is also unchanged. Now let's examine 2020 through a strategic lens, beginning with Healthcare on Slide 9. On the whole, Healthcare delivered strong results, with organic sales growth of 3.4% and EBITDA pre growth of 7.6%. That figure leaves out the Biogen provision release and reflects an organic margin improvement of plus 120 basis points — impressive given nonrecurring income was over EUR 300 million lower than in 2019. Currency movements created a substantial margin headwind. And although pandemic-related relief on Opex did help us, the underlying margin expansion remained healthy, thanks to solid top-line leverage and rigorous cost discipline. Turning to the main sales components, our highly resilient base business held broadly steady, as we recovered quickly from a pandemic-related blow to our Fertility franchise in Q2. We also advanced toward our pipeline sales ambition of EUR 2 billion by 2022, with new product sales up EUR 267 million, or plus 68% organically — clear proof of our capacity to launch and commercialize effectively even in difficult times. As anticipated, Mavenclad led the way. After a major COVID impact in spring, momentum picked up again from June, with encouraging market share gains.
Stefan Oschmann
executive2020 marked a genuine turning point for Bavencio. After we presented practice-changing first-line data, as you saw at ASCO, we gained U.S. approval in the middle of the year and have just rounded that out with approvals in Europe and Japan. A further oncology standout from 2020 was the first-in-class approval of TEP Medco in Japan — the first and only once-daily oral Met inhibitor for patients whose metastatic non-small cell lung cancer carries met X14 skipping alterations. And once again, we began 2021 on just as positive a note, with the matching approval in the U.S. That said, we keep seeing meaningful growth potential in our Healthcare business past 2022 as well. With evobrutinib, we led the way in developing BTK inhibitors for multiple sclerosis. And even with the pandemic, our Phase III trials are proceeding as planned, with data we expect to have in-house in late 2023. We are also still committed to developing bintrafusp alfa. Although the recent termination of the 037 study was disappointing, the program stays broad, testing largely independent hypotheses across different settings. We keep learning from the 037 data, and we will make sure that informs our next steps. We will update you on the second-line PTC study by end of March.
Stefan Oschmann
executiveOn our leading DDR portfolio, we recently started a Phase II trial of berzosertib in SCLC. And finally, we're enthusiastic about the in-licensing of xevinapant, which we announced on Monday. This promising Phase III compound fits our oncology pipeline perfectly and builds on our heritage in head and neck cancer. Moving to Life Science on Page 10. Performance for the year 2020 was genuinely exceptional, with organic sales growth of plus 11.8% and EBITDA pre growth of plus 17.2%. Consequently, the margin reached a record 32%, which reflects solid top line leverage, a favorable product mix and modest cost benefits given the pandemic. Our contributions to the fight against COVID-19 are numerous, and we estimate that for the whole of 2020, roughly half of the growth can be attributed to sales of products leveraged in COVID-19 vaccines, therapies and diagnostics. That also means our core business was highly robust, delivering healthy growth in line with the lower end of our midterm targets despite a significant hit to lab activity from lockdowns, particularly in Q2. From a portfolio standpoint, Process Solutions was the standout with plus 22% organic growth, followed by Research Solutions at a very good plus 5% and Applied Solutions at a solid plus 3%.
Stefan Oschmann
executiveLooking at it through the customer lens, growth was driven by farm and biotech along with diagnostics, with testing coming next — combined, those more than made up for soft industrial trends and declines in academia. A performance that strong could only happen because of the tremendous work done by our teams across the world and how tirelessly they dealt with unprecedented demand in some areas of our portfolio. Thanks to excellent crisis management, our supply chains have come through extremely well, and we've tackled bottlenecks proactively with a wide set of measures — clear allocation principles, flexible use of capacity, and major expansions of capacity, both operationally and physically. Regarding the physical capacity expansions, please note that of a total exceeding EUR 300 million, the investments in Danvers & Jeffrey matter especially in the context of COVID-19, and I'm pleased to tell you today that we are fully on track and already ramping up. Finally, 2020 was also a great year for new product introductions — examples include process pad and orchestrator as key pillars of our next-gen monoclonal antibody platform, or the award-winning Blazar platform, which delivers a fundamental shift in biosafety testing.
Stefan Oschmann
executiveLet's move to the following slide, which gives you a look at Electronics — the sector formerly known as Performance Materials. You might ask why we changed the name. The answer is straightforward: it reflects what we actually do, since nearly 90% of sales now stem from electronic materials, services and equipment, thanks to the successful transformation we've carried out over recent years. Results in 2020 got a lift from 3 quarters of consolidation benefits tied to the Versum acquisition. For the full year, organic sales and EBITDA pre growth remained negative, at minus 3.2% and minus 7.5%, respectively. Since Versum has been fully in the base from October onward, though, organic growth swung strongly positive in Q4. Solid cost management execution produced a 30.3% margin — right in line with our midterm target and down only slightly versus 2019, even with a meaningful pandemic impact that caused double-digit organic sales declines in Display and Surface solutions. End markets in both of those areas were hit hard by COVID-19 in Q2, then showed clear recovery signs during the second half. Semiconductor Solutions, by contrast — which accounts for close to 60% of sector sales — posted excellent results, with organic growth of plus 14%, pointing to further outperformance in a strong market.
Stefan Oschmann
executiveVersum integration is progressing well—actually, notably ahead of schedule. And as Kai will detail later, that reflects how strongly our teams have collaborated despite the day-to-day constraints all of us are dealing with right now. Following the first full year of integrating Versum, the product and service lineup we now offer together in Semiconductor Solutions ranks among the most extensive portfolios anywhere in the industry. Innovation gets driven not just by targeted spending in vital growth segments—like our next-gen semi materials center in Korea—but equally by big data and machine learning initiatives that lead the field and that customers value highly. Customer centricity is our focus, and what we deliver to customers is value, agility, innovative strength, application expertise and supply chain resilience. That produced results not only as a range of supplier awards but also as more than 100 semi material POR wins during 2020 by itself. With that said, I'll pass things to Marcus, who will walk you through our key financials.
Marcus Kuhnert
executiveThanks a lot, Stefan, and a warm welcome from me as well. I'm now on Slide 13, which gives an overview of our headline figures for 2020. On the whole, we're very pleased with how our key performance metrics developed. Sales grew strongly at 8.6%, and earnings grew even faster — EBITDA pre and EPS pre, excluding the Biogen provision release, were up 10.3% and 9.2%, respectively. We dealt with significant currency headwinds, though positive portfolio effects more than offset them, while nonrecurring income items, excluding the Biogen provision release, came in over EUR 300 million lower than in 2019. Please also keep in mind that, consistent with our policy, EPS pre include impairments for certain Healthcare assets in the mid-double-digit million euro range in Q4. Operating cash flow was very strong, rising 22%, which reflects strong earnings growth combined with good working capital management. As a result, we delevered quickly, with net debt-to-EBITDA improving from 2.8x to 2.1x year-on-year. Turning to the composition of growth in 2020 on Slide 14: Group organic sales growth was strong at 6%, as a moderate decline in Electronics was more than offset by moderate growth in Healthcare and very strong growth in Life Science.
Marcus Kuhnert
executiveEarnings tracked that same trend, and Stefan has already walked you through the key drivers across each of the 3 business sectors. So I'll simply add a note on corporate and other costs. Those came in above our most recent guidance, largely because of weaker-than-anticipated hedging gains, along with provisions tied to our long-term incentive program. Portfolio effects contributed positively, partly offset by unfavorable FX, which brought group EBITDA pre to EUR 5.2 billion. On an organic basis, EBITDA pre climbed 16.8%, or 8.4% when you strip out the Biogen provision release, and it was up 12.1% in Q4. But before we dig into the first-quarter details, let's briefly review our reported figures on Slide 15. EBITDA pre grew by EUR 817 million in 2020 for the reasons just mentioned, while EBIT growth came in even stronger at EUR 865 million, reflecting lower adjustments than in 2019. The financial result was EUR 30 million better, mainly on an improved interest result. The effective tax rate was 24.2%, sitting toward the low end of the guided range. As a result, reported net income and earnings per share each increased by 30%. With that, let's turn to a review of our fourth-quarter results, beginning with Healthcare on Slide 16.
Marcus Kuhnert
executiveIn Q4, organic sales growth for Healthcare came in solid at 4.1%, which reflects a broadly stable base business along with meaningful incremental contributions from our new products. Inside the base business, EBIT took accelerated to double-digit organic growth, driven mainly by the temporary supply agreement with Eli Lilly, while Rebif accelerated to double-digit organic declines against tough comps. At the same time, our Fertility franchise kept recovering, and internal medicine posted further organic growth despite initial impacts from volume-based procurement in China on Google Fresh. Turning to new product sales, Mavenclad rose 48% organically, helped by additional market share gains. Please keep in mind, though, that the dynamic market is still suppressed, which is something to watch for Q1. Bavencio climbed 90% organically, largely because of the successful U.S. launch and first-line bladder, while recent approvals in Europe and Japan for this indication laid the groundwork for further acceleration. On earnings, EBITDA pre grew 7.7% organically and therefore once again outpaced sales, reflecting continued underlying cost discipline as pandemic related cost benefits were roughly offset by lower nonrecurring income. Speaking of nonrecurring income, please note the following: income from active portfolio management landed in the mid-double-digit million euro range, both in Q4 and across 2020 as a whole, with key contributors including the out-licensing of M6594 and atacicept.
Marcus Kuhnert
executiveGSK-related deferred income came to roughly EUR 30 million during Q4, and approximately EUR 85 million across the whole year, which puts it a bit ahead of the guidance we most recently gave, reflecting the consequences of the recent 037 study discontinuation for bintrafusp. On top of that, additional review conducted after that point has shown that, regrettably, we no longer hold any right to development milestone payments from GSK. Now to the 2021 outlook for nonrecurring income. To begin with, we anticipate deferred income from GSK of approximately EUR 80 million during 2021, and we expect to recognize about EUR 20 million of that in the first quarter. Next, income from active portfolio management should land in the low- to mid-double-digit million euro range, though the chance of any such income in Q1 is small. Third, we anticipate roughly EUR 50 million of milestones, all of which are booked in Q1 thanks to the recent approvals of Bavencio in Europe and Japan. Shifting to Life Science, Slide 17. Organic sales growth in Life Science for the first quarter hit another record level, 19.3%, with 11 to 12 percentage points of that coming from COVID-19 related business. Looking at the portfolio, Process Solutions once more led the way, posting organic growth of 27%. That matches an already extremely robust Q3 and reflected solid growth in the core business alongside considerable demand for products used in COVID-19 vaccines on therapy.
Marcus Kuhnert
executiveAt the same time, order intake growth in Process Solutions sped up even more in Q4 and now sits above 60% for the entire year. That gives us solid visibility well into the third quarter of 2021. Now to the other 2 businesses. Sales and Research Solutions accelerated to a remarkable 16% plus, and Applied Solutions also improved further to a very strong 10% plus, both on an organic basis. Those 2 businesses gained from a significant year-end recovery in the core business, while at the same time we saw additional demand for our raw materials used in COVID-19 diagnostics. That demand was particularly pronounced in Research Solutions, where sales in its diagnostics segment came in above plus 50%, 5-0%. At the customer segment level for Life Science overall, pharma and biotech as well as diagnostics and testing keep posting above average growth, while industrial and academia accelerated meaningfully, with the latter even turning slightly positive in Q4. And when it comes to regions, once again, double-digit organic growth across all major regions. On earnings, EBITDA pre climbed 25.5% organically in the fourth quarter, which implies a margin of 32.2%, up 140 basis points. As in Q3, this was mainly driven by operating leverage, positive pricing and a favorable product mix.
Marcus Kuhnert
executiveSo with that said, I'll pass things over to Kai, who will walk us through a review and a deeper look at Electronics.
Kai Beckmann
executiveThanks, Marcus, and good afternoon, everyone. I'm on Slide 18 of the presentation now. Let me begin by adding to what Stefan said about the robust organic sales growth in our Electronics sector, which we have now renamed. Electronics posted organic sales growth of 8% in Q4, even with the ongoing COVID-19 impact on end markets and Surface Solutions, plus the decline in Display Solutions. A clear turnaround, marking the first organic growth in 7 quarters, came from strong above-market organic growth of 20% in Semiconductor Solutions, which as of Q4 also includes growth from legacy Versum. Along with an FX burden of 6.5%, fourth quarter EBITDA pre was also affected by year-end inventory management and the corresponding under absorption of fixed cost and production. That stemmed from the COVID-19 driven sales drop in Display and Surface Solutions over the prior 2 quarters. Even so, we managed to keep the EBITDA pre margin very close to the 30% mark. This relative margin stability, despite the adverse external effect, was achievable through continuous diligent cost management as part of the bright future transformation program, as well as significantly accelerated and increased Versum synergies, which I will walk through in a moment. I'm now moving on to Slide 19.
Kai Beckmann
executiveStefan already laid out the reasoning for why we decided to rename our Performance Materials business to Electronics, and let me restate that point. This isn't the Electronic business of Merck just because we felt it had a nicer ring to it. The reason it now carries the name Electronics is that we completed a successful transformation into a business that today provides a wide range of top electronic players with materials, services and equipment that enable the next generation of electronic devices. So if we look back and compare the business with how it stood in 2013, we haven't merely more than doubled sales through targeted investments and acquisitions — we have also become a far broader business holding leading positions as an innovation-driven supplier to the semiconductor and display industries. We can say with pride that we hold a best-in-class portfolio of capabilities, and we are confident that the return to organic growth in Q4 2020, at 8% above last year, stands as an important proof point that this transformation has succeeded. So now I'll move on to Slide 20. Innovation in the electronics industry happens at the atomic level, where our materials, service and equipment let our customers build devices that are smarter, smaller, faster and more energy-efficient.
Kai Beckmann
executiveThe importance of materials keeps increasing with every new generation of electronic devices. And our demonstrated history of deep expertise in this field underpins a very positive outlook for years ahead. Moreover, although the major rise in work-from-home and learn-from-home arrangements brings its own difficulties for numerous industries and for society broadly, it may also act as a catalyst for a paradigm shift that will further reinforce the positive momentum for technology and infrastructure in electronics. As you know, we raised our midterm guidance for organic sales growth in the sector to a CAGR of 3% to 4% at our Capital Markets Day a couple of months ago. In addition, we already raised our original Versum synergy commitments twice in 2020, and today we are significantly accelerating and increasing them yet again. And last but not least, we are even more optimistic regarding 2021 in particular, as you will see in the guidance section of this presentation. Now on Slide 21, you will find our latest Versum synergy update. As I just mentioned, we raised our targets for 2020 twice. And thanks to additional Q4 efforts of our teams, particularly in procurement and supply chain, where tracking shows that we are already -- we already fully realized EUR 50 million cost synergies in 2020.
Kai Beckmann
executiveAs we mentioned before, that speed-up enabled us to hold EBITDA pre margin near 30% even during Q4, even with a sizable FX outlay and COVID-19-related under absorption of fixed cost stemming from year-end inventory management. Moving into '21 and '22, we're both raising and speeding up our synergy goals by a large margin, and we now target the EUR 83 million level a full year sooner in '21, while once more lifting our '22 goal by more than 10% to roughly EUR 95 million. Also, as Stefan mentioned, integrating Versum has proven a highly successful journey, and we sit well ahead of plan in spite of the challenging external conditions, which really reflects how strongly our teams continue working together. With that encouraging note, I'll turn things back over to Marcus.
Marcus Kuhnert
executiveThanks, Kai. I'm turning to Slide 22 now to make a few comments about our balance sheet at year-end. The EUR 2 billion shrinkage of our balance sheet stems almost completely from FX, since a big portion of goodwill and intangible is denominated in U.S. dollar. Financial debt went down by more than EUR 1 billion, whereas cash and cash equivalents rose by roughly EUR 600 million, thanks to strong operating cash flow and steps taken to secure liquidity during the pandemic. As I noted earlier, the net debt-to-EBITDA pre ratio is 2.1x, a substantial improvement from 2.8x a year ago. The equity ratio held steady at 41%. Moving to cash flow in Q4 on Slide 23. Operating cash flow came in very strong at EUR 1.3 billion, up 87%, helped by strong earnings growth, solid working capital management and a smaller negative effect from other assets and liabilities. Investing cash flow fell significantly, largely because last year included the Versum acquisition. And financing cash flow rose considerably, reflecting a meaningful reduction in short-term bank loans in commercial papers. Lastly, let me briefly touch on CapEx. It came in above guidance because of a cash out for the opportunistic purchase of our Life Science premises in Burlington, Massachusetts.
Marcus Kuhnert
executiveIf you strip out that effect, we’d have landed in the bottom half of the guidance range. Then for 2021, our CapEx guidance is EUR 1.35 billion to EUR 1.45 billion, which is therefore above the midterm outlook we gave, largely because we need to support Life Science growth that has come in stronger than expected. So with that, I’d like to pass things over — or pass them back — to Stefan for the outlook.
Stefan Oschmann
executiveThanks, Marcus. I'm on Slide 25 now. To sum up, 2020 was a strong year for us — strong even with the difficulties we encountered. Lockdowns hit us materially in Q2, and we worked hard to manage a fast recovery during the second half while at the same time seizing new opportunities. We are contributing significantly to the battle against COVID-19, and the fact that effective vaccines arrived less than a year after the outbreak began is unprecedented. Even so, uncertainty is still high, so before I get into the specifics of our guidance for 2021, I'd like to lay out the underlying assumptions we're making about COVID-19. First and foremost, we assume vaccination penetration will rise visibly across large segments of the population beginning in summer, together with a gradual loosening of lockdowns, and that virus mutations will not be able to significantly undermine the vaccination efforts. We also believe the overall situation will get better as the year progresses. In our Healthcare business, we confirm our base business and pipeline targets despite greater uncertainty. To be more specific, we expect our Fertility franchise to keep recovering and the pandemic's effect on the ramp-up of new products to lessen. The biggest watch out here is the dynamic high efficacy market in multiple sclerosis, which remains significantly suppressed.
Stefan Oschmann
executiveFor Life Science, we expect process solutions to keep seeing extra demand, whereas research and applied solutions trends are likely to be more volatile and varied, with the net effect anticipated to be neutral to positive. In a similar vein, in Electronics we likewise anticipate a neutral to positive effect on Semiconductor Solutions, while Display and Surface Solutions ought to go back to their respective underlying trajectories. That said, let's turn to the guidance on Slide 26. As I said before, we view 2021 with optimism. At group level, organically, that translates into guidance for strong sales growth and earnings growth that is even faster, with EBITDA pre set to rise in the high single digits to low-teens, excluding the Biogen provision release. Currencies should have a negative effect of 2% to 5% on sales as well as on EBITDA pre. On Slide 27 -- let's go to Slide 27 for a summary of our key earnings drivers in 2021. In fact, there is not much to say since these align very closely with what we shared with you at our Capital Markets Day back in September. Let me simply restate that our key earnings drivers, the so-called Big 3, are very much on track. And on the basis of prudent assumptions, COVID-19 should leave them largely unaffected, with possible constraints surrounding uptake of pipeline products offset by incremental opportunities in Process and Semiconductor Solutions.
Stefan Oschmann
executiveIf you turn to Slide 28, you'll see the standard bottom-up view of the guidance. To sum up, we anticipate robust organic sales and EBITDA pre growth in Healthcare, low teens organic sales and EBITDA pre growth in Life Science, and Electronics delivering solid organic sales growth alongside solid to strong organic EBITDA pre growth. And just so we're clear, by low teens growth we mean somewhere in the range of about 10% to 13%. Now, before we begin the Q&A, let me hand it back to Marcus for a brief ESG update.
Marcus Kuhnert
executiveThank you, Stefan. As you'll recall, we unveiled our 3 new sustainability goals during the previous earnings call. So let me begin with a brief recap on Slide 30. Goal #1 for us is building a better and healthier future for more than 1 billion people in 2030. The way we'll achieve that is by harnessing innovation in science and technology to enhance quality of life for underserved populations, drawing on our expertise across all business sectors and working closely with a wide range of partners. Goal number two concerns creating sustainable value chains by 2030. To make that real, we'll heighten awareness of sustainability among our workforce and encourage supply chain stability, all while still delivering state of the art products and services to our customers, grounded in collaboration with suppliers that meet key environmental and social standards. Our third goal focuses on cutting our environmental footprint. For more detail on that, let's turn to Slide 31. Back in 2009, we had already set a 2020 goal of reducing total direct and indirect greenhouse gas emissions by 20%. And I'm pleased to tell you today that we in fact exceeded this target, cutting scope 1 and 2 emissions by 25%.
Marcus Kuhnert
executiveAlthough that left out the Versum acquisition’s effect, our fresh reduction target is built on a total of roughly 2 million tons of CO2 equivalence, Versum included. By 2030, we aim to cut our direct and indirect emissions by 50% versus 2020 and to obtain 80% of the electricity we purchase from renewable sources. Beyond that, we intend to bring down scope 3 emissions across the up and downstream value chain by 1,500 metric kilotons of CO2 equivalence. The larger objective is to reach climate neutrality in 2040 throughout our whole value chain. On water, we likewise beat our 2020 target, cutting consumption at high consumption sites by 27% compared with 2014. We also completed the rollout of a sustainable water management system at our sites, and we have set a new group of water goals for 2025 and '30, laid out in the bottom right corner of the chart. Lastly, we remain well on track toward our 2025 wage target. On my final slide today, you will see an overview of our agenda for meeting our ESG targets. All in all, the message we want to leave with you is that we treat ESG very seriously and are firmly persuaded of the shared benefits of chasing these targets for our business, for the many stakeholders involved and for society at large.
Marcus Kuhnert
executiveSo as a result, a revised compensation system for the Executive Board is going to be put to a vote at this year's AGM. More specifically, beginning in 2021, the variable pay scheme will be broadened so that it covers our 3 sustainability targets, starting with the individual modifier for the profit sharing component. Then from 2022, sustainability will also be tied into the long-term incentive plan for the Executive Board and senior management, with an effect of as much as plus or minus 20% depending on how performance measures up against appropriate ESG KPI. Stefan, over to you.
Stefan Oschmann
executiveThank you very much, Marcus, and that brings our presentation today to a close. As all of you are aware, Belen takes over from me as CEO on May 1. And I have to say, I truly can't imagine anyone better suited for the role. I'm genuinely delighted that Belem — and no one else — is the person succeeding me. Belen's record as a leader is outstanding. She played an essential part in the successful turnaround and in fundamentally reshaping our Healthcare business sector into a global specialty innovator. That has likewise been one of the central elements in the Group's wider transformation into a leading science and technology company worldwide. Having collaborated closely with Belen over the last 10 years, I can tell you as well that she is not just a tough manager and an excellent leader, but a wonderful person too, with everything needed to carry our success story forward. Belen, the floor is yours.
Belén Garijo López
executiveThanks, Stefan, for the kind words, and hello, everyone. I just wanted to offer a few comments of my own, though I'll keep them very brief given the time. First of all, science and technology innovation has been Merck's driving force for more than 350 years. And we owe it to Stefan's strong ambition and leadership, along with the commitment of our people, that Merck is better equipped to face the future than ever before. We have great business momentum across the 3 sectors, as you have seen today, and that despite the pandemic. As Stefan mentioned, I will succeed him in 8 weeks from now. And I have to say I am truly honored to follow in his footsteps and in those of multiple generations of Merck leaders who have considered themselves through custodians of our heritage, and simply the next in line. Achieving lasting leadership in science and technology innovation is paramount to me. And together with my dear colleagues, I will continue to push this leadership agenda as of May. I also expand firmly by the promises that we have previously made as part of our mid-term guidance. Overall, to create sustainable value for our owners, our investors and for the society at large, and what does it take to do that?
Belén Garijo López
executiveTo begin with, it calls on us to set the bar for how our business performs at an even greater height, while watching the market closely and tracking the competition so we grasp how to beat expectations in every sector and every function. It means converting the science and technology vision into well-grounded strategic actions and putting our weight behind excellent execution of those plans. Delivering relevant innovation and profitable growth will stay our focus in the years ahead, chiefly via the so-called Big 3 that all of you know well and where we are placing a substantial portion of our investments: Process Solution, Semiconductor Solutions and our Healthcare pipeline. Lastly, Stefan consistently maintained a very tight connection between us and the Capital Markets, acting with transparency, clear communication and fruitful dialogue. The same is what you should expect from me, and I am eagerly anticipating carrying our dialogue forward in my new role. With that, it gives me very, very great pleasure to hand the floor to the person succeeding me as Healthcare's CEO, Peter Winter. I am absolutely certain plenty of you are familiar with Peter from the roles he held previously at Almirall and Sanofi. The two of us have worked together before. He took over from me when I arrived at Merck, and I am very, very pleased that he has chosen to come on board with us.
Peter Guenter
executivePeter, the floor is yours. Thank you so much, Belen, and greetings to everybody joining us on today's call. To begin with, I want to convey my sincere appreciation to the Merck family for the confidence they showed in me, to my Executive Board colleagues for their continued backing, and finally, to our teams across the world for the warm reception and the numerous valuable exchanges we have already had since I came on board. A lot of you are familiar with me from previous interactions, but for anyone who isn't, I came to Merck from Almirall, which is based in Spain, where I held the CEO role for the last 3 years. Before that, I spent 22 years at Sanofi, including serving as a member of the Executive Committee since 2013. When Merck reached out to me, I needed little persuading that this was truly an exciting opportunity I could not pass up. Merck's global reach, along with its strong portfolio of legacy products, new launches and attractive pipeline and exciting therapeutic areas with very high unmet needs, speak for themselves. And if any proof were needed, 2020 was the perfect showcase for the solidity of the business and the organization's agility. With that said, I cannot wait to guide Merck Healthcare forward in the years to come to contribute to our performance and advance our purpose for patients.
Peter Guenter
executiveConstantin, over to you now.
Constantin Fest
executiveThanks a lot, Peter. I believe we're set to start taking questions from you now. So with that, Diana, please go ahead with the first one.
Operator
operator<<operator_script>> Our first question now comes from Matt Weston at Crédit Suisse.
Matthew Weston
analystTo start, I suppose it’s on me to say congratulations to Stefan on a long and successful career at Merck. And of course, to wish him the best at UCB and in his other pursuits in retirement, and to welcome Peter and Belen into their new positions. So, congratulations. Now on to questions—three if possible, please. The first concerns Life Science growth in 2021 and the phasing you’ve built into guidance across the year. Obviously, the division delivered an extremely strong performance in the second half of 2020. You cited accelerating momentum in the first half. What have you assumed in your plan regarding how COVID demand carries on in the second half of 2021? Second, about renaming PM as Electronics—I understand that this fully mirrors the majority of what you do. But what does that imply for the 10% of colleagues in the pigments business? Is that now clearly declared noncore? And should we expect the sales process to begin in the near future? And finally, on xevinapant. Clearly a very interesting acquisition that strategically fits with Erbitux in head and neck. As I recall, you had M3814, a DNA PK inhibitor, which was also being examined as a radiosensitizer in head and neck cancer.
Matthew Weston
analystAnd what has become of that internal development effort, now that xevinapant is the focus?
Stefan Oschmann
executiveThank you, Matthew, and thanks for those kind remarks. I'll take your first 2 questions, and the third one I'll hand over to Danny. Essentially, your question asks how durable the upside brought on by COVID-19 is, both near term and long term, and what the underlying growth looks like — that's a great question. Let me try to answer it this way. As you can see from the qualitative guidance we've given for 2021, we anticipate Life Science delivering another year of strong growth against an already strong comparable. Put differently, we're looking at 2 consecutive years of growth well above our midterm guidance, driven mainly by significant net benefits tied to COVID. To be more specific about 2021, we expect the core Life Science business to grow robustly and to be the largest contributor to growth. Beyond that, we expect to keep participating strongly. In my view, bioprocess will be the primary driver of these tailwinds, supporting production of COVID vaccines and therapies, while diagnostics will contribute less, since our participation there is more limited — supplying critical raw materials and services. For bioprocess, our absolute COVID book of business should rise more than 60% over 2020, though the contribution to total growth would be smaller given the baseline already set in 2020.
Stefan Oschmann
executiveAs we look forward, we keep evaluating how long this demand might last, and that hinges on a number of things—how several of these elements unfold, such as the speed at which vaccinations roll out, the variability of mutations, if boosters end up being required, and how long immunization lasts. Quite a few people out there assume this virus is going to become endemic, that mutations will keep emerging, and that we'll end up in an influenza-type situation. We have seen FDA guidance regarding mRNA vaccines allowing rapid adaptation of this without large clinical trials—very hard to predict, but clearly within the realm of possibility. So many moving parts, which makes it hard to gauge how much exactly we'll see in 2021. And whether this will be the peak or not. To be frank, we don't have a crystal ball on this, but you can rest assured that we'll keep participating in these tailwinds. And we will take our fair share. What you should also note is that we have—I mentioned the capacity expansion, and that is essentially online as of January. We will be fully ramping up. We're also expanding lipid capacity. We're addressing certain constraints in filter manufacturing.
Stefan Oschmann
executiveWe likewise expect our employees will be vaccinated as time goes on and that we can return to improved — to better shift models. So overall, we're quite optimistic. And sure, there could be upside in our Life Science figures, but given all the moving pieces, we believe our present forecasts are both realistic and ambitious. On the second question, PM, Electronics: we're referring to our biopharma and pharma operations, biopharma. We have lots of businesses in there that aren't bio or anything of that sort. Our Life Science business — we call it Life Science — we provide test materials to the mining sector, and so forth. So it's natural that some businesses within the portfolio don't necessarily fit precisely under the terminology we use. This morning the media asked me about Surface Solutions. My answer to the media was that the team is working extremely hard to turn that business around. We're seeing a few encouraging signals from the automotive industry, though cosmetics is still challenging. But we're working hard on turning — on bringing this business back to success. And then, on the head and neck question, I'd pass things over to Danny.
Danny Bar-Zohar
executiveYes. Thanks, Stefan. Matt, excellent question. So, as you pointed out, M38 <<inaudible>> the DNA PK is in fact yet another approach for making the tumor more sensitive to radiotherapy radiochemotherapy — mainly radiotherapy when it comes to the DNA PK. Broadly speaking, these experiments are very hard to conduct. Why? Since you definitely need to sensitize, yet you don't want to push sensitivity too far, because the moment you oversensitize, toxicity shows up, and then the radiotherapy doses have to come down, and you land yourself in a highly unpleasant vicious circle for COVID patients. But that study is being run by us at present with Eco Circuit, as you just noted. And we'll be able to report the results near the end of the second half of this year across these 2 settings, locally advanced head and neck and rectal cancer. The way it appears at the moment, it's fairly — I'd say, for the reasons I gave earlier, fairly challenging. What's beautiful about xevinapant is that — and this, you could actually see very clearly in the Phase II study — that very robust efficacy shown on local regional control, PFS and OS was achieved with no decrease in doses — in high doses of cisplatinum and radiotherapy.
Danny Bar-Zohar
executiveThat gives us confidence that sensitizing this tumor to these regimens is the right approach.
Operator
operatorWe’re now going to open the line for questions from Richard Vosser at JPMorgan.
Richard Vosser
analystTwo, please, on pharma. Regarding the Mavenclad franchise and the multiple sclerosis franchise more broadly, could you share your perspective on how the second wave is affecting overall demand for multiple sclerosis treatment? And how do you expect that to influence the ability to roll out Mavenclad across Europe, France, and the U.S., as well as the growth there? And the second question, just an update on penetration into the maintenance setting in bladder for Bavencio? Also, again, how are you seeing the impact of the lack of new patient starts or patient flow there from COVID-19? And how do you see that playing out through Q '21?
Stefan Oschmann
executivePeter will handle both of those questions.
Peter Guenter
executiveYes. Richard, thanks for those questions. Starting with Mavenclad: what we're actually seeing is that 2 dynamics are at work here. #1 is the overall size of the high efficacy market. And then, of course, there's Mavenclad's competitive position within it — we've actually observed that following the severe depression of Q2 last year, the high efficacy market recovered, but it consistently stays roughly 20% below the comparable period's levels from the prior year. And we keep seeing that, actually. So I think Marcus and Stefan also hinted at this in their prepared remarks — that this is something to watch out for. And as — hopefully, of course, with vaccination increasing and lockdowns being liberalized more and more, we'll see this effect fade as we move through the year. So that's #1. #2 concerns where Mavenclad stands within it. So we're pleased to confirm that we keep gaining market share, in both Europe and the U.S. Also don't forget that we have a kind of natural hedge in our portfolio between Mavenclad and Rebif. So if COVID-19 does kind of hit the high efficacy segment, we'll automatically get upside from Rebif, right?
Peter Guenter
executiveThat's the sort of communication foundation, if you like. So that's essentially where things stand with Mavenclad. Your second question concerns Bavencio. Unlike the high-efficacy segment of the MS market, we really aren't seeing any meaningful effect from COVID-19 on how the oncology market is developing overall, or in bladder cancer either. So Bavencio continues to track well for us. As the slides have shown, we're growing both the depth and the breadth of Bavencio prescribing. And then, naturally, we're quite excited about what I'd call the very imminent launch of Bavencio in certain European countries such as Germany, where we have immediate reimbursement access. And in Japan as well, obviously. Don't forget, when you consider the overall Bavencio picture, that the targeted population pool is in fact very large in Europe and Japan, given the considerably greater use of chemotherapy in the first-line setting. So I think you should expect that Bavencio's relative contribution in bladder cancer across Europe and Japan will be significant.
Operator
operatorOur next question comes from Sachin Jain at Bank of America.
Sachin Jain
analystThree questions, if I may. First, regarding Life Science and the CapEx increase program you outlined, could you give us some color on which capacity increases are coming online and when, just so we can get some quantification of that? And any color on the capacity bottlenecks you're seeing at present that could be unlocked, with any quantification there? That's question 1. Question 2 is a big-picture pipeline question. Pipeline sales in 2020 were roughly EUR 700 million. You clearly have a EUR 2 billion goal for '22. Should we be thinking about EUR 21 million in the middle of that range, roughly EUR 1.3 billion-ish, or given COVID, is this EUR 2 billion going to be more EUR 22 million loaded now? And then thirdly, on Healthcare cost growth, obviously a lot of cost discipline team within full year '20. Any color as to how we should think about cost growth in Healthcare this year — should we be thinking about a rebound from COVID lows? Or is the absolute cost base still flat to declining?
Stefan Oschmann
executiveThanks, Sachin. I’ll begin with your question about Life Science. Regarding the investments we have, we’re putting EUR 140 million into Darmstadt for a new membrane production plant for aseptic filters. We are in the process of investing EUR 100 million in Carlsbad, which more than doubles our existing viral and gene therapy capacity. We’ve invested EUR 59 million in medicine, mostly for ADC, ADC production, and we’ve invested EUR 40 million in Danvers and Jaffray. We’re also creating 700 additional new jobs for single-use and filtration production. Since the last earnings call, we have kept working to maximize output from all existing assets so we can meet customer demand. You remember we’ve discussed that we have a strict prioritization principle in place. That means we prioritize COVID, which means non-COVID work gets deprioritized. Some of this demand may be lost, but we think the majority of the demand will come back later. Our headcount, as I said, has increased from 3,800-or-so to much more than that. And as part of our continuous improvement program, we use Lean 6 Sigma tools to drive our yield and our efficiency programs so that we can create maximum output.
Stefan Oschmann
executiveIn Massachusetts, we've opened an expansion of roughly 6,000 square meters for the mobile single-use product, the single-use product. Basically, we expect this to double our capacity. And in Jeffrey in New Hampshire, we have a new manufacturing line for the filtration, virus or filtration systems that also went live in December and will significantly increase our output. You've also probably heard about the partnerships we have with the various mRNA companies, namely BionTech, but also other companies on enhancing our output for lipid. And you may have -- you may remember that we bought Mtech, a company in Hamburg that brings us into the active drug substance business for RNA. And we're reviewing our long-range demand for our product portfolio against the expected capacity. And we will continue to define a list of expansions and accelerate that further in a very timely fashion. And above all, we will be monitoring the situation. We're prepared to adapt our initiatives. And we think that we have sufficient capacity available in the medium term. And I talk to our main customers. Our customers also want us to produce single-use reactors in Europe because of the U.S. Wartimes Act. We have very concrete plans and talking to a specific government in this context.
Stefan Oschmann
executiveThe feedback we're getting from our mRNA and vaccine customers regarding the ramp-up has been quite positive. And they expect that a number of these issues — and we're not alone in this; our competitors find themselves in very similar circumstances — will cease to be bottlenecks before long. With that, I'll turn things over to Peter.
Peter Guenter
executiveYes. Thanks, Stefan. Now regarding that EUR 2 billion pipeline ambition question — the short answer is yes. We're still committed to that ambition. As for whether the ongoing COVID impacts on the higher efficacy market in MS have made this somewhat more back-loaded, that may well be the case, but of course it depends on how fast the high efficacy market normalizes...
Stefan Oschmann
executiveAlright, I'll take the third one — Cost and Healthcare in 2021. First off, please keep in mind that at this early <<inaudible>> stage we're guiding on individual cost lines within our 3 sectors. Still, just to offer a bit of, let's say, food for thought or flavor: when we look at COVID-19 cost savings across the whole group, we saw a net figure of roughly EUR 150 million arise in 2020. And since Healthcare is quite exposed to travel as well as to external events, you can assume that we have, I'd say, a somewhat overproportionate portion of that EUR 150 million landing in Healthcare. For the group as a whole, I think it's fair to assume that we would — that our aim is to make some 50% of those net savings sustainable into 2021. So that would clearly be an upside for Healthcare cost next year. On the other hand, please bear in mind the most recent news you've received on xevinapant — that will, until the launch date in 2025, also add some additional R&D costs, predominantly to our cost lines. We've obviously done the math, and we believe that, for the next 3 years, that will be a high double-digit million euro amount year-on-year additional in our cost lines.
Stefan Oschmann
executiveOne final thing: kindly note that all of that is already baked into our 2021 guidance.
Operator
operatorWe’ll go ahead and take the following question from Peter Vedult at Citi.
Peter Verdult
analystTwo questions only, both on Life Sciences once more and on Semiconductor Solutions. At Q3, I believe you mentioned visibility of 6 to 9 months for Life Science. Given the demand spike there and in semi as well, could you update us on your current thinking regarding how much visibility you now have in those businesses? Then second, a two-part question for Peter on Healthcare. At this point, are you prepared to provide any kind of outline of the commercial peak sales potential you foresee for xevinapant? And then, more strategically, as the balance sheet deleverages and with the current pipeline and with you stepping in as the new Healthcare head, should we expect in-licensing efforts to become a much more visible element of your strategy going forward?
Stefan Oschmann
executiveOkay, so here's a question. I'll begin with the Life Science one, then pass it to Kai for the semi question, and after that Peter for Healthcare. Yes, we do enjoy solid visibility into the order book, and that's what underpins our confidence in a continuing trend through this year. We work in close partnership with our customers so that we can successfully fulfill their requirements, and that provides us with this solid visibility now well into the second half — into the second half. We anticipate a strong first half of 2021 and a strong second half as well. But versus the second half, comps were stronger. That's what you would need to factor in. We see no indication whatsoever of any deceleration on this front. Let me repeat that: at this stage, nobody can clearly forecast how the COVID situation will develop. Nobody knows what kind of variance will arise. How the vaccination regime will look going forward. Nobody can at this stage. But there is a high likelihood that this virus becomes endemic. And if it does become endemic, we see an increased trade of mutations, particularly in the Southern Hemisphere, where few people are being vaccinated, which is — I think that leads — should lead us to a situation where we should assume a significant probability that COVID vaccinations stay with us.
Stefan Oschmann
executiveSo with that in mind, we're really discussing trends over a longer horizon. One final point on this. Nearly every day, I'm on the phone with heads of government and people from the EU Commission from various countries, and they tell us that one lesson to come out of this endemic is that their healthcare systems have to be more resilient, that they need to establish safety stocks of reagents for diagnostics, and that they want to build vaccine and biologics infrastructure locally in various countries — and those governments want to partner with a company like ours. That's yet another positive factor for the midterm. With that, I'll hand it to Kai.
Kai Beckmann
executivePeter, I’ll address the semi question. On our end, visibility has not shifted a great deal over this period. So there is — we’re using the same market forecast for their new REIT, and with the high variability at present, since nobody truly knows how 2021 will ramp in terms of capacity as well. So a lot of our customers are investing considerably, and those extra capacities need to come online first before additional opportunities appear. That said, I think you see the — our midterm forecast, you see in this year’s forecast being fairly aggressive. We recognize there’s a chance to move up to our customers’ currently available capacity with somewhat accelerated growth rates. That said, one cautionary note: the Q4 organic growth rate is, of course, exceptional. Additional factors from our equipment business were included as well. So that is not the run rate going forward. That said, you could understand our long-term midterm forecast is very valid, and we are ranging at the upper end of that forecast for our semi business.
Peter Guenter
executiveYes. So Peter, regarding that question, first, on the matter concerning Stefan. To give you a sense of the market size we're discussing. Head and neck cancer continues to be a highly significant cancer globally. It has a substantial impact on quality of life and social interactions — affecting how patients look or eat, in brief — and also very cool long-term outcomes, with a 5-year survival rate under 50%. So I think that clearly shows the degree of unmet need that remains in this type of market. Now regarding xevinapant, we'll be examining locally advanced high-risk head and neck patients who are unresectable. Both in the U.S. and in Europe, we're looking at patient pools exceeding 20,000 patients each. The other thing — if we succeed in both studies, that is to say the cisplatin eligible and cisplatin ineligible and assistant ineligible patient population, we believe xevinapant actually has blockbuster potential. So that covers your question about xevinapant. Your second question concerned a more frequent, I would say, in-licensing strategy. Frankly, I think we're agnostic to it.
Peter Guenter
executiveIt really comes down to the opportunity itself. It comes down to whether there's a strategic fit. It comes down to how strong the biology is or how strong the POC is. And I think, if you look at it from — with this angle to the xevinapant opportunity that we licensed, that is exactly what we want to look at. It's within our TA. It is — it really fits us like a hand in a glove. We have deep, deep knowledge of the head and neck market, both commercially, medically and from an R&D perspective. And if we come across other late-stage opportunities for in-licensing that really are a good fit for our portfolio, we will definitely consider those.
Operator
operatorWe'll go ahead and take the next question, which comes from James Quigley at Morgan Stanley.
James Quigley
analystJames Quigley here from Morgan Stanley. First, regarding the farm deal: what's your thinking on the locally advanced head and neck cancer landscape? CATIA dominates the metastatic head and neck cancer setting and, I believe, has data in the locally advanced setting this year versus your data, which would arrive in 2024. How do you think about the comparison with that? And could standard of care shift somewhat before you launch? Then a clarification on that as well. In the appendix, EUR 300 million of the EUR 380 million are approval milestones and the focus head and neck indications. Can you confirm that covers the first 2, cisplatin eligible and cisplatin ineligible? And then the second question on the binary tract data. Apparently it's been in-house for quite a while now. Is there anything — I mean, are you committed to limit to by the end of March? I mean, is there anything particular or unique about the data set that will require some additional analysis or a longer analysis than perhaps we were used to when other assets have come in-house and then been reported?
James Quigley
analystAnd how do you see the commercial opportunity for FinFET Trust in the BTC indications?
Stefan Oschmann
executiveDanny will take those questions.
Danny Bar-Zohar
executiveThank you, Stefan. Now, on the xevinapant question and KTWO in head and neck — that's clearly a topic we examined quite carefully as part of due diligence. And broadly, as you noted, most of the benefit immuno-oncology has delivered in squamous cell carcinoma of the head and neck has in fact come from the relapsed and metastatic setting, and that is not where we sit. Ours is the locally advanced setting, so it's a different context. You correctly pointed out that this KEYNOTE trial differs greatly from the trial design of the Phase III with xevinapant. In the KEYNOTE trial, we're actually talking about high-dose chemotherapy with hydrose chemotherapy followed by maintenance with pembrolizumab travis — quite similar. It's much shorter, of course, with concomitant chemo-radiotherapy plus 3 additional cycles of xevinapant only, for a total of 6 cycles. So with this regimen — or in fact with half of this regimen in the Phase II study — the results in terms of PFS and OS showed more than 50% reduction. And the risk of these events was something that raised more than one eyebrow within the medical community. Now, if I — if we look correctly at clinicaltrials.gov for the KEYNOTES trial, the results should be available around April, May.
Danny Bar-Zohar
executiveSo we're going to have to dig into that. That's the technical side of things, but it's also worth examining the pembrolizumab data in the locally advanced setting from the PembroRad study. That was a combination with radiotherapy versus Erbitux in 130 patients. And in that setting, I think we could sum it up quite well. From whatever angle you look at it, there was nothing there in terms of efficacy. You also remember -- we also remember the avelumab study, the Javelin head and neck trial in the locally advanced setting combined with chemo radiotherapy, which is quite similar to what we're doing. That was an all-comer study. And as you also recall, there was nothing there either in the all-comer population in terms of efficacy. Now the only hint, and I think that -- I guess that's the reason you're asking, is the PD-L1 high subgroup in that study that showed some kind of efficacy. But if we're using the same method, if -- let me put it this way, MSD used the same method as we used in the Javelin study in terms of PD-L1, then we're talking about something like 17%, 1-7% population. And with 17% of the population, while their analysis is, at least according to what's in the public domain, not defined like that.
Danny Bar-Zohar
executiveI think we feel quite confident that, given our proof-of-concept and the design of the xevinapant trial, we'll be able to demonstrate efficacy, and overall we'd be right around that potential. Now on the BTC data. As Stefan mentioned at the start, yes, the data has been in-house for several weeks, I'd say. But I think, to your question about what's missing — it's really the 037. The 037 results actually caught us somewhat by surprise. And we locked this study not in the way we typically look at studies. It was locked in haste, and data keeps flowing in. So we learn from the data each and every day, and we did prioritize — I personally prioritized this, with the bintrafusp team working closely alongside GSK and with external consultants, to inform additional insights on that. Now in terms of — so we'll be able to communicate the BTC second-line results by the end of this month, as we committed to and as we promised. Now, of note, there are other studies ongoing: BTC first line, recruiting cervical second line, fully recruited. And we expect the data to be in-house by the end of this year.
Danny Bar-Zohar
executiveAnd then there's the lung 005 study as well. So that is definitely a commitment on our part. Any further insights we generate regarding the biturafusp study, we'll share them jointly with GSK.
Stefan Oschmann
executiveLet's take the next question.
Operator
operatorUp next, we'll take the following question from Luisa Hector at Berenberg.
Luisa Hector
analystTurning to Electronics, I was hoping you might share some thoughts on the visibility you have there. Semis clearly had a very strong Q4. How far into 2021 can you see? And on surface, you mentioned continued pressure in cosmetics. Is that still the main area of weakness? Do you expect it to recover as COVID vaccinations pick up? And across Electronics overall, you talk about holding a 30% margin. But given the stronger outlook for '21, what's the focus for some margin expansion? Also, would you mind commenting on how Mavenclad splits between U.S. and ex-U.S.? And any thoughts on patient retention in Germany?
Stefan Oschmann
executiveLisa, thank you for those questions about Electronics. Let me begin with the visibility piece, which I attempted to explain somewhat more broadly in the earlier question. Right now, it is difficult to have a truly precise forecast in our industry. Market projections differ widely, and they shift considerably from one quarter to the next. What we naturally observe, of course, is how our customers behave. And I believe over the past 2 years we did quite well in providing you with fairly precise forecast figures, and we delivered in line with those figures. Would I view the coming 12 months the same way? We don't possess a crystal ball, though. So we have to examine our customers' CapEx spending, and whether fresh capacity comes online, to give us further opportunities. Broadly speaking, what we can see spans no more than 6 to 9 months in our industry. Turning to Surface Solutions and cosmetics, particularly cosmetics — and above all decorative cosmetics, which is where we operate. Our primary area within cosmetics is decorative, and it has been hit hard by lockdowns. When people stay at home, they don't apply any lipsticks.
Stefan Oschmann
executiveThat’s something that will keep being the case until the lockdown situation gets easier. But still, I think you should keep in mind that cosmetics isn’t a major portion of Performance Materials or Electronics as things stand right now. So that business accounts for only a small share. And it will certainly bounce back once vaccinations happen and lockdowns are eased. As for holding the 30% margin, I think the math there is quite straightforward. So if we bring in more high-margin business, we’d rather put our R&D spending into that area to kind of create extra sales growth. When you’re above a 30% margin, additional sales growth delivers far greater returns over the long run. So that’s the reason we don’t plan to simply keep growing margin and ignore the opportunity on the R&D side. That’s why you’ll see in our forecast for this year a fairly bullish forecast on the bottom line as well. So it’s not that we’re easing off on this side. But don’t expect us to just put the money into the bottom line and not invest in R&D. Peter?
Peter Guenter
executiveYes. Thanks for the question, Luisa. On the U.S. versus ex U.S. split, we don't disclose sales by region. As for patients returning after year 2, which I believe was also part of what you asked, I can confirm that E2 returns remain high. In fact, that has improved considerably since the pandemic began, as confidence has grown among both HCPs and patients. And of course, in this case, having an oral solution available certainly helps.
Stefan Oschmann
executiveI believe there's room for 2 additional questions. So let's take the next one, please.
Operator
operatorSimon Baker of Redburn has our next question.
Simon Baker
analystI have two questions. First, on Healthcare. R&D spending in Q4 came in a bit above what we had anticipated. And I also — sorry, this is at the group level. And I also notice there was a restructuring charge of a comparable amount in Healthcare. So are those 2 connected? Or is there some other explanation for why R&D was somewhat higher this quarter? And then, staying on Healthcare, after the disappointment with bintrafusp in non-small cell lung cancer, I was wondering whether you could remind us and bring us up to date on what you're doing and what your ambitions are in non-small cell lung cancer? I saw that M1231 entered the clinic in January but doesn't appear to have made it onto the pipeline slide yet. So I wonder if you could just tell us what else you have going on in that area.
Stefan Oschmann
executiveMarcus, would you like to kick things off?
Marcus Kuhnert
executiveRight. First, I should point out that we wouldn’t necessarily have, say, one quarter’s R&D spending match the next one exactly. So there can be some quarter-to-quarter fluctuations. And certainly, the R&D figure for the first quarter includes a portion of the provisions we’re building for the Bright Future Healthcare transformation program, which is actually spread across all the cost lines and has, in a sense, also pushed up the R&D cost in Q4.
Stefan Oschmann
executiveYes. Thank you. On the pipeline front. I'd say the big-picture message is that we remain strongly dedicated to non-small cell lung cancer. A few points worth keeping in mind. To start with, with bintrafusp, there are in fact 2 trials currently running in non-small cell lung cancer. You're all aware of this. As a reminder for everyone, we have a Phase III study underway with avelumab, under the Bavencio name, which should report out near the close of the second half of the year. It's an event-driven trial, and it's actually testing a far more concentrated or high dose of avelumab in that setting against chemotherapy. Right now, though, the greater hopes rest on tepotinib, which was approved recently in the U.S. So we've earmarked that for MEDX14 operations in non-small cell lung cancer. And we're quite enthusiastic about the study now under way in MET-amplified patients, the resources — it's a combination with avelumab, in connection with the INSITE II study, which is enrolling as we speak. The field is very keen on this, since evidence keeps building that MET amplification is the reason — the principal reason — for lack of response to osimertinib, which is gaining market share rather substantially.
Stefan Oschmann
executiveThis is yet another illustration of our work in that area. Regarding your question on the bispecific ADC, MET 1-AGFR and M1231, that's another source of excitement for us. And I believe we conveyed that, and a clinical trial is already underway. Several weeks ago, we had the first patient in this study. And one of the indications being tested there is, once again, non-small cell lung cancer. So from that standpoint, I think we are strongly committed to this deal. Let's take the last question now, please.
Operator
operatorGreat. And our final question this afternoon comes from David Evans at Kepler Cheuvreux.
David Evans
analystSo I have just 2 questions about Healthcare, if I may. The first concerns Bavencio in bladder cancer outside of the U.S. You did address this, but I was hoping you could share some insights into what reimbursement rates are likely to look like across different countries? And what other limiting factors might exist once reimbursement is secured? At the end of the day, would you anticipate a fairly rapid launch uptake in markets once reimbursement comes through? Or are there notable limiting factors we should keep in mind? Should we genuinely expect any meaningful sales in bladder cancer in Europe this year, or at least in 2022 — would you expect a significant level of sales from Europe? And then second, just on Glucophage, we haven't really seen any notable dip in sales yet, but I was wondering whether you could give us some color on what to expect in the coming year for Glucophage, particularly in China?
Stefan Oschmann
executivePeter?
Peter Guenter
executiveYes. David, thanks for asking. Regarding your first question about Bavencio: as you correctly noted, approval came on January 22 in Europe. We are, of course, working hard with all the key countries to get pricing and access procedures both underway and completed as quickly as possible. You're aware that in most European countries this takes time. There are a few exceptions to that rule — Germany, for instance. So we're actually getting ready for the launch in Germany right now, and we'll roll it out over the coming days. The same applies to Japan. In other countries, we're trying to take advantage of every opportunity we have to accelerate sales further, which will then arrive in 2022. For example, we're taking part in ATU in France. And I should also mention that the development of that ATU in France is, I'd say, extremely interesting. On your second question about Glucophage in China: indeed, we entered VBP Round III. You know that all the metformins in that round were "Chinese" manufacturers. And we expect the full impact of this VBP to actually begin as of the first quarter of this year, 2021.
Peter Guenter
executiveLet me remind you of two points. First, 80% of the hospital population is accessible to the winners, so 20% of the hospital population stays open to the non-winners — roughly 50% of the total market. Then there is another portion, around 30% of the total market, that sits in retail, I believe, and naturally the VBP does not affect it. In short, roughly 45% of the Chinese market remains open to Glucophage. I would also remind you that there are, naturally, very, very strong tailwinds behind the overall metformin market in China, thanks to the diabetes epidemic we are seeing there, and from a market standpoint we will keep benefiting from that tailwind. And finally, Glucophage in China is, naturally, only one part of the overall base business. When you consider the overall base business, Glucophage China actually accounts for around about 5% of the total, right, since, as you know, the base business holds much more than just the cardiovascular metabolic and then the chronology fertilities in that bucket, et cetera, et cetera — Erbitux sits in that bucket. So that gives a bit of perspective on the Glucophage China question.
Constantin Fest
executiveThanks. Thanks. Stefan, I’ll hand it to you now for the closing remarks, please.
Stefan Oschmann
executiveThanks so much, Constantin, and I appreciate all of you for the interest you keep showing in Merck. As you're aware, this marks my final earnings call here at Merck. So let me close on a personal note, if I may. Over these 10 years I've had interactions with many of you — probably most of you, I'd guess — and for the most part I've really enjoyed them. You've taught me a great deal. This has never been a one-way street. We take very seriously, and have always taken very seriously, what we hear from you and what the influencers are thinking. The exchange with you matters to us. So thank you for your critical questions and the many fruitful discussions we've had. You've helped me become a better businessmen, and Merck a better company. I'm retiring from Merck, though not necessarily from business, and I'd be surprised if one or the other of us didn't have contacts in the future — with me in a different type of inclination. I sincerely wish you all the best, both personally and professionally. And thank you, again, and goodbye.
Operator
operatorThanks, everyone, for being here. That brings this call to a close. You can now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.